Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Senseonics Holdings, Inc. (SENS) provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Senseonics is a medical technology company focused on the development and manufacturing of long-term implantable continuous glucose monitoring (CGM) systems, and its filings offer detailed insight into its financial condition, capital structure, and corporate actions.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and financial statements related to its Eversense 365 and Eversense E3 glucose monitoring products. Form 8-K current reports disclose material events, such as preliminary financial results, the implementation of a 1-for-20 reverse stock split, special stockholder meetings, and updates on commercialization plans and collaborations.
Investors can also review proxy materials, such as the DEF 14A definitive proxy statement for the special meeting of stockholders that authorized the reverse stock split and proportional reduction in authorized shares. In addition, a Form 25 filing documents the voluntary removal of Senseonics’ common stock from listing and registration on the NYSE American in connection with the transfer of its listing to the Nasdaq Global Select Market.
Through this page, users can follow how Senseonics reports on topics such as revenue updates, capital structure changes, and governance matters. Real-time updates from EDGAR ensure that new filings, including Forms 8-K, 10-Q, and 10-K, appear as they are submitted. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections, and clarify technical language, making it easier to understand how Senseonics’ regulatory disclosures relate to its long-term implantable CGM business.
For those researching SENS, this filings page serves as a central location to review the company’s official SEC documents, track its corporate history, and analyze how its medical technology operations and public company obligations intersect.
Senseonics Holdings, Inc. files its Annual Report describing a diabetes-focused medical technology business built around Eversense, a long-term implantable continuous glucose monitoring system. The company highlights FDA approval and U.S. launch of its 365-day Eversense 365 system in 2024.
The report details a major shift in commercial strategy as Senseonics acquires Eversense commercial assets from Ascensia, regains U.S. marketing rights, and from January 1, 2026 is entitled to 100% of Eversense revenues in key European territories. The company outlines pivotal trials, upcoming Gemini and Freedom sensor platforms, extensive patent protection through 2049, and notes that 41,770,466 shares of common stock were outstanding as of February 20, 2026.
Senseonics Holdings, Inc. reported strong growth for the fourth quarter and full year 2025 while continuing to invest heavily in commercialization of its Eversense 365 long-term CGM system. Q4 revenue rose to $14.3 million, up from $8.3 million, driven mainly by U.S. sales.
For 2025, total revenue increased to $35.3 million from $22.5 million, and gross profit improved sharply to $15.8 million from $0.5 million as one-time transition charges rolled off and margins on the 365-day product improved. The annual net loss narrowed to $69.1 million, or $1.66 per share, from $78.6 million, reflecting better gross profit offset by higher selling, general and administrative expenses as the company took Eversense commercialization and distribution back in-house and ramped direct-to-consumer marketing.
Cash, cash equivalents and investments totaled $94.3 million with indebtedness of $35.3 million at December 31, 2025. For 2026, Senseonics expects global net revenue of $58–$62 million, implying 65–76% growth, and targets gross margins of about 50% as it completes the transition from Ascensia and expands Eversense 365 globally and into automated insulin delivery integrations.
Senseonics Holdings, Inc. furnished a current report to share business updates and preliminary, unaudited financial information for the year ended December 31, 2025. The company did this by issuing a press release, which is attached as Exhibit 99.1, and referenced in the report for details on preliminary revenue and year-end cash, cash equivalents and restricted cash levels.
The company notes that these figures are estimates, have not been reviewed or audited, and may change when its 2025 financial statements are finalized and audited. The report emphasizes that statements about expected fourth quarter 2025 and full-year 2025 results are forward-looking and subject to risks described in prior annual and quarterly reports.
Senseonics Holdings, Inc. reported an insider equity transaction by its Chief Financial Officer, Frederick T. Sullivan. On 11/15/2025, 6,402 shares of common stock were disposed of at a price of $6.26 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations on vesting restricted stock units. After this tax withholding, Sullivan beneficially owned 150,626 shares of Senseonics common stock in direct ownership. This type of transaction reflects administrative share withholding rather than an open-market sale.
Senseonics Holdings, Inc. insider reports routine share withholding for taxes. A director and Chief Medical Officer filed a Form 4 showing the disposition of 4,605 shares of common stock on 11/15/2025 at $6.26 per share, coded as an "F" transaction, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units. After this transaction, the insider beneficially owned 123,948 shares of Senseonics common stock. The company effected a 1-for-20 reverse stock split of its common stock effective October 17, 2025, and the share amounts reported in this filing have been adjusted to reflect that reverse split.
Senseonics Holdings, Inc. (SENS)11/15/2025, 10,317 shares of common stock were withheld and disposed of at $6.26 per share to cover withholding tax obligations tied to the vesting of restricted stock units. After this tax-related transaction, the reporting person beneficially owned 259,979 shares of common stock directly. The company also notes that, effective October 17, 2025, it implemented a 1-for-20 reverse stock split, and all share amounts in the report have been adjusted to reflect this reverse split.
Senseonics Holdings, Inc. (SENS)11/15/2025, 5,997 shares of common stock were withheld at $6.26 per share to cover withholding taxes upon the vesting of restricted stock units. Following this transaction, the reporting person beneficially owned 144,434 shares of common stock in direct ownership form.
The filing also notes that, effective October 17, 2025, Senseonics implemented a 1-for-20 reverse stock split of its common stock, and the share numbers in the report have been adjusted to reflect this reverse split.
Senseonics Holdings, Inc. (SENS) reported an insider equity transaction by its President and CEO, who is also a director. On 11/15/2025, the executive disposed of 27,067 shares of common stock at $6.26 per share, coded "F" for a tax-related withholding event.
After this transaction, the executive directly beneficially owned 634,018 shares of Senseonics common stock. The filing explains that the shares were withheld to satisfy withholding tax obligations upon the vesting of restricted stock units, meaning the disposition was tied to equity-compensation taxation rather than an open-market sale.
Senseonics Holdings, Inc. filed Form 25, notifying the removal of its Common Stock ($0.001 par value) from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 on the NYSE American. This filing signals the company’s intent to delist its common shares from that exchange pursuant to the Exchange Act’s procedures.
Senseonics Holdings (SENS): A company director reported an open‑market purchase of common stock on 11/10/2025. The filing shows 10,000 shares acquired at a weighted average price of $6.55, with individual trades executed between $6.48 and $6.58. Following this transaction, the director beneficially owned 74,708 shares, held directly.
The share counts reflect the issuer’s 1‑for‑20 reverse stock split that became effective on October 17, 2025.